Mettler-Toledo International Inc. (MTD) Stock Price & Analysis
Mettler-Toledo International Inc. (MTD) closed at USD 1,684.64 on Thursday, October 22, 2026, up 0.40% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 1,677.94; the Oct 22, 2026 session ranged USD 1,666.13–1,713.39 on volume of 229,704 shares. Market capitalization is $33.75B, with a 52-week range of USD 1,023.05–1,713.39 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:49 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MTD.md
Key facts (MTD)
- Last four reported quarters (through Jun 30, 2026): revenue $4.13B, net income $906M (21.9% margin), free cash flow $864M (SEC filings).
- Valuation: P/E 37.3x (avg 32.4x at the last 3 fiscal year-ends), net debt $2.06B.
- 2 of 80 tracked superinvestors hold MTD (13F, Q2 2026): 1 new, 0 added, 1 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 5 Form 4 filings, $6.1M; 5 not under a Rule 10b5-1 plan ($6.1M); 2 by opportunistic insiders (2 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Total return with dividends: 1Y +17.2% vs S&P 500 +14.9%; 5Y +14.6% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 12.09, revenue estimate $1.07B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (MTD)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $3.72B | $3.92B | $3.79B | $3.87B | $4.03B | $4.13B |
| Gross profit | $2.17B | $2.31B | $2.24B | $2.33B | $2.39B | — |
| Net income | $769M | $873M | $789M | $863M | $869M | $906M |
| EPS (diluted) | $32.78 | $38.41 | $35.90 | $40.48 | $42.05 | — |
| Free cash flow | $801M | $738M | $861M | $864M | $849M | $864M |
| Gross margin | 58.4% | 58.9% | 59.2% | 60.1% | 59.4% | — |
| Net margin | 20.7% | 22.3% | 20.8% | 22.3% | 21.6% | 21.9% |
| Revenue growth | +20.5% | +5.4% | -3.4% | +2.2% | +4.0% | — |
| Cash + short-term investments | $98.6M | $96.0M | $69.8M | $59.4M | $66.9M | — |
| Total debt | $1.68B | $2.01B | $2.08B | $2.01B | $2.15B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (MTD)
P/E 37.3x · P/S 8.2x · EV/Sales 8.7x · P/FCF 39.1x · P/B 2632.3x · FCF yield 2.56% · Earnings yield 2.68% · Buyback yield (TTM) 2.30% · Net debt $2.06B · EV $35.8B
P/E at fiscal year-ends: Dec 2025 33.2x, Dec 2024 30.2x, Dec 2023 33.8x.
Superinvestors (SEC 13F-HR, Q2 2026) (MTD)
2 of 80 tracked investors hold MTD. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Torray Funds | 0.29% | $2.1M | Reduced -0.4% | |
| Wallace Weitz | Weitz Investment Management | 0.23% | $3.3M | New position |
Insider sales (SEC Form 4, open-market, last ~7 months) (MTD)
0 of 5 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-27 | Kaltenbach Patrick | President and CEO | 942 | $1.3M | 17.4% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-08-05 | Salice Thomas P | Director | 417 | $601K | 0.8% | No | Too little history (no open-market trades in 2023) |
| 2026-08-03 | Salice Thomas P | Director | 415 | $600K | 0.8% | No | Too little history (no open-market trades in 2023) |
| 2026-08-03 | Keller Gerry | Head of Process Analytics | 240 | $343K | 48.1% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-08-03 | Vadala Shawn | Chief Financial Officer | 2,240 | $3.2M | 28.6% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (MTD)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | Morgan Stanley | Target raised | Equal-Weight | $1450 → $1575 |
| 2026-10-07 | Barclays | Target raised | Overweight | $1575 → $1700 |
| 2026-09-02 | Rothschild & Co | Initiated | Sell | $1200 |
| 2026-09-01 | RBC Capital | Initiated | Sector Perform | $1515 |
| 2026-08-04 | Morgan Stanley | Target raised | Equal-Weight | $1275 → $1450 |
| 2026-08-03 | Evercore ISI Group | Target raised | Outperform | $1350 → $1500 |
| 2026-08-03 | Wells Fargo | Target raised | Equal-Weight | $1225 → $1450 |
| 2026-08-03 | Barclays | Target raised | Overweight | $1300 → $1575 |
| 2026-08-03 | Stifel | Target raised | Buy | $1400 → $1600 |
| 2026-07-31 | Jefferies | Target raised | Buy | $1400 → $1580 |
| 2026-07-06 | Evercore ISI Group | Target raised | Outperform | $1300 → $1350 |
Total return (dividends reinvested) (MTD)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +17.2% | +14.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +17.2% | +2.8% |
| Volatility (annualized) | 32.0% | 31.4% |
| Max drawdown | -31.9% (Nov 2025→May 2026) | -42.5% (Dec 2021→Oct 2023) |
MTD revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| US Operations | $352.5M | 34.3% | -5.4% |
| Western European Operations | $227.0M | 22.1% | +7.1% |
| Other Operations | $204.1M | 19.9% | +9.0% |
| Chinese Operations | $187.2M | 18.2% | +15.6% |
| Swiss Operations | $56.5M | 5.5% | +14.0% |
| Total revenue | $1.03B | 100% | — |
MTD revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product | $753.0M | 73.3% | +2.6% |
| Laboratory products and services | $552.6M | 53.8% | +2.7% |
| Industrial products and services | $417.7M | 40.7% | +5.8% |
| Service | $274.3M | 26.7% | +10.2% |
| Retail products and services | $57.1M | 5.6% | +12.6% |
| Total revenue | $1.03B | 100% | — |
MTD revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Americas | $402.3M | 39.2% | -2.8% |
| Us Operations segment Member | $352.5M | 34.3% | -5.4% |
| Asia | $331.3M | 32.2% | +12.3% |
| Europe | $293.7M | 28.6% | +7.2% |
| Western European Operations | $227.0M | 22.1% | +7.1% |
| Other Operations | $204.1M | 19.9% | +9.0% |
| Chinese Operations | $187.2M | 18.2% | +15.6% |
| Swiss Operations segment Member | $56.5M | 5.5% | +14.0% |
| Total revenue | $1.03B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
MTD company outlook (results filed Jul 30, 2026)
- “Based on today's assessment, management anticipates local currency sales for the third quarter of 2026 will increase approximately 4%.”
- “Adjusted EPS is forecast to be $12.00 to $12.15, a growth rate of 8% to 9%.”
- “For the full year 2026, management anticipates local currency sales will increase approximately 4% to 5% excluding tariff refunds to customers.”
- “Adjusted EPS is forecast to be in the range of $47.15 to $47.50, representing growth of approximately 10% to 11%.”
Quoted word-for-word from the SEC 8-K results press release.
MTD analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $12.09 | $12.06 | +0.3% | $1.07B | 11 |
| Next quarter (ends Dec 2026) | $14.89 | $14.91 | -0.2% | $1.18B | 10 |
| Current fiscal year (ends Dec 2026) | $47.35 | $46.66 | +1.5% | $4.24B | 13 |
| Next fiscal year (ends Dec 2027) | $51.76 | $51.27 | +1.0% | $4.44B | 13 |
MTD options: expected move
Options price a move of about ±9.5% (±$159.25) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±4.1% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 42.0% | ±9.5% |
| Dec 18, 2026 | 56 | 36.4% | ±11.5% |
| Jan 15, 2027 | 84 | 34.8% | ±13.4% |
| Apr 16, 2027 | 175 | 34.3% | ±19.0% |
| May 21, 2027 | 210 | 34.2% | ±20.8% |
| Aug 20, 2027 | 301 | 33.0% | ±24.0% |
| Nov 19, 2027 | 392 | 32.5% | ±26.9% |
30-day implied volatility 41.6% vs 26.5% realized over the last 30 trading days. Put/call ratio (volume) 1.04. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:49 UTC)
| Price | USD 1,684.64 |
|---|---|
| Change | ▲ 0.40% (up) |
| Previous Close | USD 1,677.94 |
| Open | USD 1,675 |
| Day Range | USD 1,666.13 – 1,713.39 |
| 52-Week Range | USD 1,023.05 – 1,713.39 |
| Volume | 229,704 shares |
| Market Cap | $33.75B |
| Exchange | NYQ |
Technical Analysis (MTD)
Nexqual's technical model rates MTD "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:49 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 78.05 (overbought) |
| vs SMA50 | Above (USD 1,461.42) |
| MACD | 60.94 (positive) |
Earnings (MTD)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD 12.09 |
| Revenue Estimate | $1.07B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 11.46 vs est 10.8 ▲ beat |
| 2026-03-31 | USD 8.91 vs est 8.71 ▲ beat |
| 2025-12-31 | USD 13.36 vs est 12.81 ▲ beat |
| 2025-09-30 | USD 11.15 vs est 10.66 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:49 UTC.
Financials & Fundamentals (MTD)
| Total Revenue | $4.13B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +4.50% |
| Gross Margin | +60.26% |
| Operating Margin | +31.20% |
| Profit Margin | +21.91% |
| Debt / Equity | 166.68 |
| Current Ratio | 1.12 |
| Total Cash | $51.38M |
| Total Debt | $2.14B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $863.97M (20.9% of revenue) |
Source: Nexqual, October 23, 2026 at 09:49 UTC.
Financial Health Score (MTD)
Nexqual rates Mettler-Toledo International Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:49 UTC.
| Growth | Mixed — Revenue +4.0% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 60%, operating 31% (last 12 months) |
| Balance Sheet | Critical — $51M cash and investments vs $2.11B debt (Jun 2026, SEC) |
| Cash Flow | Strong — FCF $864M (last 4 quarters to Jun 2026, SEC), 21% margin |
| Efficiency | Mixed — No data |
Ownership (MTD)
| Insider Ownership | +0.44% |
|---|---|
| Institutional Ownership | +105.52% |
| Shares Outstanding | 20.04M |
| Float | 19.93M |
| Short % of Float | +4.06% |
Source: Nexqual, October 23, 2026 at 09:49 UTC.
From Mettler-Toledo International Inc.'s Latest SEC 10-K Filing (filed 2026-02-06)
Key Strengths & Strategy (as disclosed to the SEC)
- We hold over 5,600 patents and trademarks (including pending applications), primarily in the United States, Canada, Switzerland, China, the European Union, Germany, the United Kingdom, Italy, France, Japan, South Korea, Brazil, and India.
- Over the last three years, we have invested $574 million in research and development ($199 million in 2025, $189 million in 2024, and $185 million in 2023), which is approximately 5% of net sales for each year.
- We generally manufacture critical components, which are components that contain proprietary technology.
- The close relationships and frequent contact with our large customer base allow us to be the trusted advisor of our customers, which provides us with high-quality sales opportunities as well as innovative product and application ideas.
Legal & Regulatory Risks (Item 1A, quoted)
- We may be adversely affected by tariffs and other trade restrictions and by failure to comply with regulations of governmental agencies or by the adoption of new regulations.
- We may be adversely affected by environmental and climate change laws, regulations, and expectations.
- We may be adversely affected by regulations and market expectations related to sourcing and our supply chain, including conflict minerals.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ILMN | Illumina, Inc. | USD 269.4 | ▼ 4.76% |
| DGX | Quest Diagnostics Incorporated | USD 243.28 | ▲ 1.82% |
| LH | Labcorp Holdings Inc. | USD 329.93 | ▲ 1.91% |
| IDXX | IDEXX Laboratories, Inc. | USD 566.76 | ▲ 2.4% |
| WAT | Waters Corporation | USD 455.59 | ▼ 0.41% |
| IQV | IQVIA Holdings, Inc. | USD 278.32 | ▲ 0.61% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:49 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt